BENITEC BIOPHARMA INC
BNTCNASDAQTrading Snapshot
- Day Range
- $13.27 – $13.70
- 52-Week Range
- $9.85 – $16.76
- Volume
- $4.44B
- Avg Volume
- $3.24B
- Shares Outstanding
- 34.4M
- Next Earnings
- Oct 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $70,051
- Last Q Revenue
- $17,429
- P/E Ratio
- —
- P/S Ratio
- 6758.0x
- EPS (TTM)
- $-1.11
- Dividend Yield
- —
Why Investors Own BNTC
- ✓High-growth profile — revenue up -6.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BENITEC BIOPHARMA INC
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.